Loading…
Employees: 753
Size Medy-Tox (086900.KS) is a South Korea Health Care company (Biotechnology) with a market value of $310M, the 454th largest of 495 South Korea companies the cockpit tracks. Shares closed at ₩64,000 on 6 Nov 2026.
Performance Over six months the shares fell 39.3%, against -22.3% for the median peer and -24.5% for the South Korea market (cap-weighted) — 5th lowest of 18 in its peer set.
Growth Revenue grew 7.0% over the last twelve months (peer median +7.4%); the operating margin is 6.9% (peer median -554.7%).
Valuation It trades at 19.9× forward earnings against a peer median of 11.4× (most expensive of 4).
Price implies For today's price to make sense, revenue must grow about 6% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is -6 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 2.5 points below its cost of capital (5.3% WACC).
Next results Next results expected around 16 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩251B | ₩247B | ₩229B | ₩221B | ₩195B |
| Revenue growth | — | +8% | +3% | +13% | — |
| Gross profit | ₩149B | ₩137B | ₩132B | ₩128B | ₩124B |
| EBITDA | ₩37.4B | ₩36.6B | ₩40.3B | ₩32.7B | ₩61.8B |
| Net income | ₩15.3B | ₩16.6B | ₩17.0B | ₩9.76B | ₩37.0B |
| Free cash flow | ₩54.5B | ₩45.8B | ₩24.5B | ₩2.98B | ₩14.2B |
| Capital expenditure | ₩30.3B | ₩34.2B | ₩18.7B | ₩37.5B | ₩25.1B |
| Total debt | ₩125B | ₩76.6B | ₩87.2B | ₩82.8B | ₩121B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 086900.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -5.2% | -13.5% | 7th highest of 20 |
| 6-month return | -39.3% | -22.3% | 5th lowest of 18 |
| Distance from 52-week high | -54.6% | -52.5% | 9th lowest of 20 |
| Revenue growth (TTM) | +7.0% | +7.4% | 7th lowest of 14 |
| Operating margin | 6.9% | -554.7% | 4th highest of 14 |
| Forward P/E | 19.9× | 11.4× | most expensive of 4 |
| Growth the price implies (Req g, 7 yrs) | 6.0% | n/a | — |
| Growth delivered (Del g) | +11.9% | n/a | — |
| Hurdle (Req g minus delivered) | -5.9 pp | n/a | — |
| ROIC minus cost of capital | -2.5 pp | -76.1 pp | 3rd highest of 10 |
| EV / EBITDA | 13.4× | 6.6× | 2nd most expensive of 4 |
| Net debt / EBITDA | 2.0× | -0.4× | 2nd most indebted of 4 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Medy-Tox 086900.KS | South Korea | $310M | -39% | +7% | 7% | 19.9× | 6.0% | +11.9% |
| X4 Pharmaceuticals XFOR | United States | $315M | -28% | -52% | -555% | n/a | n/a | n/a |
| Century Therapeutics IPSC | United States | $304M | -27% | -100% | n/a | n/a | n/a | n/a |
| Galectin Therapeutics GALT | United States | $317M | +50% | n/a | n/a | n/a | n/a | n/a |
| Circio CRNA.OL | Norway | $303M | -14% | n/a | n/a | n/a | n/a | n/a |
| Kyverna Therapeutics KYTX | United States | $302M | -48% | n/a | n/a | n/a | n/a | n/a |
| HJ Science 6132.HK | Hong Kong | $300M | n/a | +621% | -967% | n/a | n/a | n/a |
| Agenus AGEN | United States | $323M | +87% | +30% | 27% | n/a | n/a | n/a |
| TransThera Sciences (Nanjing) 2617.HK | Hong Kong | $323M | -83% | n/a | -751% | n/a | n/a | n/a |
| IMPACT Therapeutics 7630.HK | Hong Kong | $325M | n/a | +395% | -173% | n/a | n/a | n/a |
| Laekna 2105.HK | Hong Kong | $328M | -57% | n/a | -57% | n/a | n/a | n/a |
| AP Biosciences 6945.TWO | Taiwan | $330M | -32% | -100% | n/a | n/a | n/a | n/a |
| Benitec Biopharma BNTC | United States | $333M | -22% | n/a | n/a | n/a | n/a | n/a |
| Alector ALEC | United States | $340M | +9% | -83% | -857% | n/a | n/a | n/a |
| Cuorips 4894.T | Japan | $341M | -9% | -51% | -947% | n/a | n/a | n/a |
| Fennec Pharmaceuticals FENC | United States | $344M | +42% | +78% | -3% | 18.7× | n/a | n/a |
| ProKidney PROK | United States | $345M | -39% | +55% | -21,665% | n/a | n/a | n/a |
| Viva Biotech 1873.HK | Hong Kong | $354M | -14% | +7% | 10% | 9.5× | 5.6% | +19.1% |
| Medtide 3880.HK | Hong Kong | $358M | -9% | +14% | 36% | 11.4× | n/a | n/a |
| Allogene Therapeutics ALLO | United States | $359M | -54% | -100% | -3,886% | n/a | n/a | n/a |
| Aspen Neuroscience ASPE | United States | $362M | n/a | n/a | n/a | n/a | n/a | n/a |